2024-11-16 10:48:36
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
Corporate/ 2023-07-24
PharmAbcine Receives IND Approval from t...

DAEJEON,South Korea,May 23,2023--PharmAbcine Inc. (KOSDAQ: 208340ks),a clinical-stage biotech company focusing on the development of next-ge...

BrightInsight Named 2023 Global Company of the Year by Frost & Sullivan for Enabling Better Patient Outcomes with Digital Solutions
Health/ 2023-07-22
BrightInsight Named 2023 Global Company ...

BrightInsight\'s Platform and out-of-the-box Disease Management Solution speed time to market for patient apps,enabling biopharma to differe...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release